Helixgate https://validator.w3.org/feed/docs/rss2.html STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments Erica Schwartz confirmed as CDC director, filling nearly yearlong vacancy COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID Lilly confident in slow and steady Foundayo launch, as ex-US sales shine STAT+: Could poop pills be the next treatment for food allergies? STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety Lilly, FDA retatrutide biologic dispute comes to a head as submission nears Attovia adds to biotech IPO momentum with $289M offering Immune Pathway Identified That Prevents C. albicans Infection from Becoming Deadly Lilly climbs, Novo falls as obesity drug battle intensifies Electrical Stimulation’s Effects on Neurons, Gene Expression Mapped in Living Human Brain Tissue No deal between AstraZeneca and BMS, senior source insists: Reuters Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees Over 1/3 stay in biopharma jobs for health insurance, poll finds Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts STAT+: Moderna launches early trial of Ebola mRNA vaccine Novo CEO sees innovation as a matter of survival amid pipeline setbacks Enzene Targets Local Biomanufacturing with New Solutions A COPD drug from China draws $115M in venture funding The main therapy used for children with autism faces changes under Medicaid Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms Fur Real: Biotech Startup Eliminates Major Dog Allergen in Beagle Pups Using CRISPR Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them 5 NextGen winners who went public this year (and which ones are hiring) 4 potential biotech M&A targets, plus a pretty sure bet from J&J Onshoring Is Here. The Hiring Wave Is Still a Decade Out Home Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges Lisata axes 72% of workforce following failed merger with Kuva AI Uses MRIs to Generate Brain Aging Maps for Neurodegenerative Disease Research Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy Beyond the Technology: AI Readiness in Regulated Laboratories STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans Vertex’s biggest overhang: a rival 50 times smaller Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine J&J pharma leader to retire; Krystal slumps on gene therapy miss As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger Icon inks Anthropic partnership to deploy Claude into clinical trials STAT+: Are AI scribes medical devices? UK regulator weighs in. Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure $6.7m awarded to pancreatic cancer research projects Latigo, BlossomHill detail IPO plans for pain and cancer push Trans federal employees sue over revoked health coverage NSF-Funded Test Bed Lets Researchers Program Automated Biomanufacturing Workflows Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab Vertex unfazed by competitive IgAN space as FDA verdict looms